Stock Analysis of Aligos Therapeutics Inc (ALGS) - Birds Eye View

1W   2W   1M   3M   1Y   2Y   5Y   
Overview
Code ALGS
Close 0.730
Change -0.0462 / 5.95 %
Volume 184447
Vol Change 38807.00 / 26.65 %
IndustryBiotechnology
SectorHealthcare
AIO Strength Index
Technical StrengthStrong Bearish
Growth Index Low Growth Stock
Value Index Poor Value Stock
Profitability Index Poor Profitability Stock
Stability Index No Significant Stability


Fundamental View of Aligos Therapeutics Inc
PE (TTM)

-286.67

Very Poor
Price / Book

395.32

Very Poor
Price / Sales

2229.33

Very Poor
Piotroski F Score

3.0

Not Good
Market Cap

54785.35 K

Enterprise Value

-77679.65 K

ROA (TTM)

-83.61

Very Poor
ROE (TTM)

-137.90

Very Poor
Net Margin (TTM)

-777.66

Very Poor
Revenue

11.66 %

15529.00 K
Net Profit

8.71 %

-87679.00 K
Debt to Equity

0.0352

Excellent
Altman Z Score

-4.90

Very Poor
Quick Ratio

0

Poor
Cash Ratio

5.68

Very Good


Highs/Lows of Aligos Therapeutics Inc
PeriodOld priceStock ReturnS&P 500 ReturnsHighLowHigh DateLow Date
One Week0.8101 9.85 % 1.85 % 0.83770.719907-May-2410-May-24
Two Week0.782 6.61 % 2.41 % 0.8710.719902-May-2410-May-24
One Month1.04 29.78 % 1.20 % 1.090.719911-Apr-2410-May-24
Three Month0.69 5.84 % 3.90 % 1.20.6204-Mar-2415-Feb-24
Six Months0.6987 4.52 % 18.29 % 1.20.544904-Mar-2411-Dec-23
One year1.2 39.14 % 26.22 % 1.340.5415-May-2324-Oct-23
Two year1.16 37.04 % 30.53 % 2.410.5417-Jan-2324-Oct-23


Technical View of Aligos Therapeutics Inc
RSI

37.29

Neutral
MACD

-0.0374

Whipsaw
ADX

17.04

Neutral
Super Trend

0.942

Mild Bearish
Williams %R

-94.15

Mild Bearish
CCI

-135.59

Mild Bearish


EMA 5

0.769

Strong Bearish
EMA 15

0.800

Strong Bearish
EMA 50

0.844

Mild Bearish
EMA 100

0.829

Whipsaw
SMA 100

0.807

Whipsaw
SMA 200

0.787

Whipsaw
SMA 5 / 20

0.778 / 0.796

Mild Bearish
SMA 15 / 50

0.791 / 0.901

Strong Bearish
SMA 50 / 200

0.901 / 0.787

Strong Bullish




Charts of Aligos Therapeutics Inc


Returns of Aligos Therapeutics Inc with Peers
Period / StockALGSCDTXAVROEUDA
1 Week-9.85%-2.80%0.820%24.02%
1 Mth-29.78%-33.92%-1.60%20.65%
3 Mth5.84%-16.48%-6.82%37.04%
6mth4.52%-21.04%-10.22%70.77%
1 Year-39.14%-45.23%83.04%52.05%
2 Year-37.04%-11.63%48.19%-77.44%
5 Years--71.18%-93.71%-
charts-
View All Together in Chart      Inline           Tile

Compare Fundamentals of Aligos Therapeutics Inc with Peers
Ratio / StockALGSCDTXAVROEUDA
PE-286.67-1.324.49-1.25
P/B395.326.180.6094.11
ROA-83.61-45.7211.42-130.87
ROE-137.90-468.7313.570
Debt To Equity0.0352-0.1580.0093-1.05
Revenue15529.00 K
11.66 % 		56541.00 K
12.05 % 		0
% 		9840.71 K
6.67 %
Net Income-87679.00 K
8.71 % 		-30697.00 K
3.01 % 		-4092.00 K
96.14 % 		-24949.25 K
2984.88 %


Technicals of Aligos Therapeutics Inc with Peers
Technical / StockALGSCDTXAVROEUDA-
ADX17.0416.3030.0830.37
CMF-0.167-0.146-0.02210.276
MFI25.7867.6763.0874.56
RSI37.2941.4148.0563.57
MACD Abv SignalFalseTrueTrueTrue
Price Above 50 MAFalseFalseFalseTrue-
Price Above 200 MAFalseFalseFalseTrue-


About : Aligos Therapeutics Inc

Address : One Corporate Drive, South San Francisco, CA, United States, 94080
Tel : 800 466 6059
URL : https://www.aligos.com
Code : ALGS, ISIN : US01626L1052, Exchange : NASDAQ, Country : USA
Fiscal Year End : December
IPO date : 16_Oct_2020
Employee Count : 66

Aligos Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapeutics to address unmet medical needs in viral and liver diseases. Its drug candidate, ALG-055009, a small molecule THR-ß agonist that is in the Phase 2a clinical trial for the treatment of non-alcoholic steatohepatitis (NASH). The company also develops ALG-000184, a capsid assembly modulator, which is completed Phase 1b clinical trial to treat chronic hepatitis B (CHB); and ALG-125755, a siRNA drug candidate, which is in Phase I clinical trial for the treatment of CHB. In addition, it develops ALG-097558, which is in Phase 2 clinical trial for the treatment of coronavirus. The company has entered into license and research collaboration agreement with Merck to discover, research, optimize, and develop oligonucleotides directed against a NASH; license agreement with Emory University to provide hepatitis B virus capsid assembly modulator technology; license agreement with Luxna Biotech Co., Ltd. to develop and commercialize products containing oligonucleotides targeting hepatitis B virus genome; and research, licensing, and commercialization agreement with Katholieke Universiteit Leuven to develop coronavirus protease inhibitors. Aligos Therapeutics, Inc. was incorporated in 2018 and is headquartered in South San Francisco, California.


Note : All Data Generated at the End of Trading Hours (EOD Data)